Article Text

PDF
▼Bevacizumab and ▼cetuximab for colorectal cancer
  • Relevant BNF section: 8.1.5

Abstract

Every year in the UK, around 16,000 people die from colorectal cancer, the second commonest cause of death from cancer in the UK after lung cancer.1 Over half of all people with colorectal cancer eventually die of metastatic disease.2 While median survival has increased with optimal use of combination chemotherapy,3,4 only a small minority of patients are still alive 5 years after diagnosis of metastases.5 ▼Bevacizumab (pronounced be-va-see-zoo-mab) (Avastin - Roche) and ▼cetuximab (se-tuks-ee-mab) (Erbitux - Merck) are two new monoclonal antibodies licensed for treating patients with metastatic colorectal cancer. Here we assess their efficacy and safety.

Statistics from Altmetric.com

  • Relevant BNF section: 8.1.5

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.